Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection.
The goals of this retrospective study were to determine whether there is a threshold hepatitis B virus (HBV) DNA value associated with spontaneous or antiviral therapy-related hepatitis B e antigen (HBeAg) clearance. We also investigated whether there is an HBV DNA value that can be used for differentiating inactive carriers from patients with HBeAg-negative chronic hepatitis B. HBV DNA levels in sequential serum samples of 165 Chinese patients with different stages of chronic HBV infection were quantified by a polymerase chain reaction (PCR)-based assay. Our results showed that almost all of the patients (89%) who remained HBeAg-positive had HBV DNA levels that were persistently above 10(5) copies/mL. Serum HBV DNA levels decreased by a mean of 3 log(10) in patients with HBeAg loss, but 51% had levels above 10(5) copies/mL at the time HBeAg first became undetectable. Mean serum HBV DNA levels were significantly lower in HBeAg-negative patients. HBV DNA value above 10(5) copies/mL would exclude all inactive carriers, but 45% of patients with HBeAg-negative chronic hepatitis would also be excluded if testing were only performed at presentation and 30% would be excluded if testing were performed on 3 occasions. In conclusion, serum HBV DNA levels decreased significantly in patients with HBeAg loss, but there was no threshold HBV DNA level associated with HBeAg clearance. Given the fluctuating course of HBeAg-negative chronic hepatitis, it is not possible to define a single cutoff HBV DNA value for differentiating inactive carriers from patients with HBeAg-negative chronic hepatitis.
Chu
Chi-Jen
CJ
Department of Medicine, Division of Gastroenterology, University of Michigan Medical Center, Ann Arbor, MI, USA.
Hussain
Munira
M
Lok
Anna S F
AS
D000328:Adult; D000410:Alanine Transaminase / Q000097:blood; D000998:Antiviral Agents / Q000008:administration & dosage; D002353:Carrier State / Q000097:blood / Q000175:diagnosis; D004279:DNA, Viral / Q000097:blood*; D005260:Female; D005838:Genotype; D006513:Hepatitis B e Antigens / Q000235:genetics; D006515:Hepatitis B virus / Q000235:genetics / Q000302:isolation & purification*; D019694:Hepatitis B, Chronic / Q000097:blood / Q000175:diagnosis* / Q000188:drug therapy; D006801:Humans; D007372:Interferons / Q000008:administration & dosage; D008297:Male; D011401:Promoter Regions, Genetic; D012074:Remission Induction; D012189:Retrospective Studies
D000998:Antiviral Agents; D004279:DNA, Viral; D006513:Hepatitis B e Antigens; D007372:Interferons; D000410:Alanine Transaminase